Jazz Pharmaceuticals (JAZZ) PT Raised to $179 at Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Tech drags S&P 500, Nasdaq lower as more Iran sanctions, Nvidia earnings loom
- Oil slips ahead of US announcement of new sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Tech drags S&P 500, Nasdaq lower as more Iran sanctions, Nvidia earnings loom
- RUM Group signs $13.7 billion GPU services deal, issues warrants
- Funds sell $44bn in semiconductors on AI concerns
- XPeng Inc. (XPEV) Misses Q2 EPS by 100c ; Provides Outlook
Jazz Pharmaceuticals (JAZZ) Tops Q3 EPS by 51c, Raises FY Guidance
November 5, 2019 4:22 PM ESTJazz Pharmaceuticals (NASDAQ: JAZZ) reported Q3 EPS of $4.10, $0.51 better than the analyst estimate of $3.59. Revenue for the quarter came in at $538 million versus the consensus estimate of $524.39 million.
GUIDANCE:
Jazz Pharmaceuticals sees FY2019 EPS of $15.50-$16.15, versus the consensus of $15.03.... More
